The FDA issued a Warning Letter to a California drug compounder over alleged “false or misleading claims” about its Pred-Moxi-Brom (PMB) product. While the concerns in the June 30 letter to Imprimis Rx LLC in Carlsbad, Calif., are usually expressed by the Center for Drug Evaluation and Research’s Office of Prescription Drug Promotion, the letter was issued by the FDA Office o... Read More